The research began with a question that has become increasingly important in cancer biology: why do apparently ordinary cells surrounding a tumor so often predict how aggressively the disease will progress? Fibroblasts are connective-tissue cells that help organize and maintain organs, repair injuries, and produce components of the extracellular matrix, the intricate protein scaffold surrounding cells. Inside tumors, however, fibroblasts can be reprogrammed into cancer-associated fibroblasts, or CAFs. Rather than behaving as passive structural support, these cells can remodel tissue, influence blood vessels, alter cancer-cell growth, and regulate immune activity. Much of the detailed work on CAFs has focused on pancreatic cancer, but their roles in lung cancer have been less completely understood. Columbia researchers therefore examined lung-tumor fibroblasts at the level of individual cells, looking for subtle molecular differences that would be hidden in an averaged tissue sample.

To perform that analysis, the team used single-cell transcriptomic profiling, a technique that measures patterns of gene activity in thousands of individual cells. Every cell contains essentially the same DNA, but different cell types activate different subsets of genes, creating distinctive molecular signatures. By sequencing messenger RNA from individual fibroblasts, scientists can determine which genes are switched on and group cells according to their functional programs. This approach is particularly powerful in tumors, where malignant cells, immune cells, blood-vessel cells, and connective-tissue cells coexist in constantly changing states. In the mouse model of lung cancer, the analysis revealed a fibroblast population that had not been recognized in healthy lung tissue. These cells expressed CHL1, a gene not normally associated with fibroblasts in the un diseased organ, providing a molecular marker for tracking the newly defined population.

Further experiments showed that CHL1-positive fibroblasts were not simply bystanders in the tumor microenvironment. They were positioned in a way that enabled them to influence the distribution of regulatory T cells, commonly known as Tregs. Tregs are essential immune regulators. They restrain potentially damaging immune reactions and help prevent the body from attacking its own tissues. In the lungs, this function is especially important because the organ is constantly exposed to airborne particles, microbes, and environmental antigens. Without effective immune braking, each breath could provoke inflammation. Cancer exploits that protective system. When Tregs accumulate near a tumor, they can suppress the activity of cytotoxic T cells and other immune mechanisms capable of recognizing and killing cancer cells. The newly identified fibroblasts therefore appear to convert a normal tissue-protection program into a localized shield for malignant cells.

The molecular connection between the fibroblasts and the Tregs involved a signaling protein called CXCL9. Chemokines such as CXCL9 act like molecular guidance cues, creating signals that influence the movement and positioning of immune cells. The Columbia team found evidence that the CHL1-positive fibroblasts use CXCL9 to recruit regulatory T cells to the edge of lung tumors. That location may be strategically important: the tumor border is where immune cells encounter cancer-associated signals and where the balance between attack and tolerance can determine whether malignant cells are contained or allowed to expand. In the mouse experiments, genetically disrupting components of this signaling system reduced the accumulation of Tregs around tumors. With fewer regulatory cells present, immune activity against the cancer increased and tumor control improved. The results suggest that the fibroblast–CXCL9–Treg pathway is not merely correlated with immune suppression but contributes directly to the tumor’s ability to resist immune elimination.

The discovery also highlights why cancer immunotherapy cannot be understood by studying immune cells alone. Treatments that activate T cells may fail when the surrounding tissue continually instructs those cells to remain inactive. Fibroblasts can provide that instruction through chemokines, matrix proteins, growth factors, and contact-dependent signals. In this case, the cancer-associated fibroblast population appears to create an immunological compartment in which suppressive T cells are concentrated and potentially supported. Blocking the pathway could therefore complement existing therapies by changing the physical and chemical environment around the tumor. The researchers emphasize that the findings do not yet constitute a treatment for patients. The experiments were performed in mouse models and through analyses of human tumor samples, and additional work will be needed to determine whether CXCL9 or CHL1 can be safely targeted without disrupting the immune regulation required for healthy lung function.

Evidence that the same fibroblasts occur in human disease came from tumor specimens and clinical information held in Columbia’s tissue bank. In human lung cancers, tumors containing greater numbers of CHL1-positive fibroblasts showed weaker immune responses and were associated with shorter progression-free survival. Progression-free survival measures how long patients live without their disease worsening, making the association clinically meaningful even though it does not by itself prove causation. The human observations align with the mouse experiments, in which disruption of the relevant signaling pathway reduced Treg accumulation and permitted stronger antitumor immunity. Together, the results suggest that CHL1-positive fibroblasts could serve as a biomarker identifying tumors with a particularly suppressive microenvironment. They might also help researchers select patients for future therapies designed to block Treg recruitment or dismantle the cellular structures that support immune escape.

One of the most intriguing questions is how these cells arise. The CHL1-positive fibroblasts were not detected as a normal fibroblast population in healthy lungs, raising the possibility that they are produced when existing stromal cells are transformed by signals from the developing tumor. Cancer cells, inflammatory molecules, low oxygen levels, and mechanical changes in the tissue can all alter fibroblast behavior. A normal fibroblast exposed to that combination may change its gene expression and acquire a new identity, including the ability to produce chemokines that reshape local immunity. If researchers can identify the signals that trigger this transformation, it may become possible to prevent the protective niche from forming before it is fully established. Such an approach could be different from directly killing tumor cells: instead, it would remove the support system that allows them to remain hidden.

The study adds to a growing picture of lung cancer as an ecosystem rather than a mass of malignant cells acting alone. Tumors survive through interactions with blood vessels, connective tissue, immune populations, and the biochemical environment surrounding them. The newly described fibroblasts demonstrate how a rare or previously overlooked cell state can have an outsized effect by organizing other cells in the tumor neighborhood. Their discovery was made possible by single-cell technology, but the broader challenge is now to translate a molecular signature into a practical intervention. Future studies will need to determine whether CHL1-positive fibroblasts are present across different lung-cancer subtypes, whether their abundance changes during treatment, and whether targeting CXCL9 affects the effectiveness or toxicity of immunotherapy. For now, the work offers a compelling explanation for one route by which lung tumors evade immune attack—and identifies a hidden cellular accomplice that may be vulnerable to precision treatment.

Type 1 diabetes develops when the immune system destroys the pancreatic beta cells responsible for producing insulin. Islet transplantation can restore insulin secretion by introducing healthy insulin-producing cells into a recipient, but transplanted islets are vulnerable to immune rejection and inflammatory damage. Current strategies often rely on immunosuppressive drugs, which can expose patients to infection and other complications, or on semipermeable polymer capsules intended to shield the cells from immune attack. These capsules must be thick enough to provide protection, yet thin enough to permit rapid molecular exchange. That trade-off has made long-term cell survival difficult: thicker barriers can delay the movement of glucose and insulin, while thinner barriers may offer inadequate protection or fail to form consistently around the entire cell cluster.

The new system takes its inspiration from the zona pellucida, a specialized extracellular layer that surrounds mammalian oocytes. During reproduction, this structure provides mechanical protection and participates in highly selective molecular interactions, including the recognition of sperm. Rather than reproducing the zona pellucida’s exact biological composition, the researchers adapted its design principles: a cell-associated layer is assembled through molecular recognition, formed directly at the cell surface and then strengthened into a stable hydrogel. This biomimetic concept is intended to combine the precision of biological recognition with the tunability of synthetic materials.

At the centre of the technique are aptamers, short single-stranded nucleic acid sequences that can be engineered to bind selected molecular targets. In this case, aptamer-directed recognition brings the components needed to construct the capsule into close proximity with the islet surface. Once localized, the components undergo crosslinking, a chemical process that connects individual polymer chains into a three-dimensional network. The resulting hydrogel is then hardened into a coherent coating approximately 20 micrometres thick. Because the capsule is assembled where recognition occurs, rather than being produced around the cells in a separate bulk process, it can form closely around the islet surface and avoid the uneven coverage associated with some conventional encapsulation techniques.

The researchers report a 100 per cent encapsulation efficiency, meaning that every targeted islet received a capsule under the described conditions. The encapsulation was also droplet-free. This is technically important because droplet-based microfluidic and emulsification systems can expose cells to interfaces, shear forces, changes in osmotic conditions or additional processing steps. The new procedure instead takes place in a liquid environment compatible with living cells and does not require harsh factors. According to the study, the islets experienced no detectable loss of viability or function during the encapsulation process, suggesting that the protective coating can be applied without sacrificing the biological performance it is designed to preserve.

The capsule’s thinness is another central feature. A 20-micrometre barrier is substantially thinner than many earlier protective coatings, reducing the distance that glucose must travel to reach beta cells and that insulin must cross after secretion. In principle, shorter diffusion paths can help the encapsulated islets respond more rapidly to changes in blood glucose. The hydrogel must nevertheless remain sufficiently stable to prevent direct contact between donor cells and the recipient’s immune system. The study’s design therefore treats thickness, molecular permeability and structural integrity as interconnected engineering parameters rather than as separate objectives. The researchers’ results indicate that the biomimetic coating achieved this balance well enough to support islet activity after transplantation.

The team tested the encapsulated allogeneic islets in immunocompetent diabetic mice. “Allogeneic” refers to cells transferred between genetically different individuals of the same species, a setting in which immune recognition and rejection remain relevant. “Immunocompetent” mice retain functioning immune systems, making the model more demanding than experiments conducted in animals whose immune responses have been deliberately suppressed or genetically impaired. Following transplantation, the treated animals achieved normoglycaemia, or blood-glucose levels within the normal range. Most maintained normoglycaemia for more than 100 days, indicating that the encapsulated islets continued to release biologically active insulin over an extended period despite being exposed to a functioning host immune system.

The findings suggest that the capsule did more than merely preserve the physical structure of the transplanted islets. To regulate blood glucose, beta cells must sense glucose fluctuations, produce insulin in response and release the hormone in a controlled manner. The maintenance of normoglycaemia implies that the coated islets retained sufficient glucose responsiveness and secretory capacity after transplantation. At the same time, the long duration of glycaemic control suggests that the hydrogel remained in place and continued to provide meaningful protection. The study does not establish that the coating completely eliminates immune recognition, nor does it show that the strategy would work indefinitely, but it demonstrates a sustained therapeutic effect in a stringent preclinical model.

The work also illustrates why cell protection is increasingly being approached as a problem of biological interface design. A capsule placed around a living cell is not simply a passive wall: it must regulate transport, withstand the surrounding tissue environment, avoid damaging the enclosed cells and limit harmful interactions with host biology. By using aptamers to direct assembly at the cell surface, the researchers created a process that resembles biological self-organization more closely than conventional bulk encapsulation. Such molecular precision could eventually be adapted to other cell therapies, including engineered endocrine cells or replacement cells intended to treat diseases beyond diabetes, although each application would require its own safety and compatibility testing.

For patients, the potential significance lies in the possibility of restoring insulin production without continuous systemic immunosuppression. However, the results remain preclinical. Human islets are larger, transplantation procedures are more complex and immune reactions in people can involve both cellular and antibody-mediated mechanisms. Long-term capsule stability, vascularization, inflammation, manufacturing scale-up and the fate of the material after transplantation will all need to be examined. Researchers will also need to determine whether the thin hydrogel can protect cells from the full range of immune and inflammatory threats encountered in the human body. Even so, the study presents a notable advance: a stress-free, droplet-free and molecularly guided method that creates a remarkably thin protective coating while preserving islet function. In diabetic mice with intact immune systems, that coating supported sustained glycaemic control, offering a new direction for the engineering of transplantable living cells.

Subject of Research: Biomimetic hydrogel encapsulation of pancreatic islets for immune protection and sustained blood-glucose regulation in type 1 diabetes.

Article Title: Biomimetic zona pellucida-encapsulated islets for sustained glycaemic control in immunocompetent mice.

Article References: Lee, K., Wang, X., Wen, C. et al. Biomimetic zona pellucida-encapsulated islets for sustained glycaemic control in immunocompetent mice. Nature Biomedical Engineering (2026). https://doi.org/10.1038/s41551-026-01775-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01775-8

Keywords: Islet transplantation, type 1 diabetes, cell encapsulation, hydrogel, aptamers, zona pellucida, biomimetic engineering, immune protection, beta cells, glycaemic control

Cancer cells have evolved numerous methods for evading the immune response, and the secretion of extracellular vesicles represents one of the most cunning. These vesicles, which can include exosomes and microvesicles, are released into the tumor microenvironment and the systemic circulation, acting as messengers that impact distant and proximate cells alike. Zeng and colleagues highlight how these vesicles carry a cargo rich in proteins, lipids, and genetic material, which play pivotal roles in modifying immune responses and promoting a supportive environment for tumor growth.

One of the critical aspects of tumor-derived extracellular vesicles is their ability to alter the metabolic landscape of immune cells. Zeng et al. provide compelling evidence that these vesicles can induce a shift in the metabolism of T cells and macrophages—key players in anti-tumor immunity. This reprogramming leads to what some researchers have termed an “immunosuppressive phenotype,” which compromises the ability of immune cells to recognize and attack tumor cells effectively. By hijacking these metabolic pathways, tumors can effectively shield themselves from immune surveillance.

Furthermore, another layer of complexity is added by the notion that tumor-derived EVs can influence not just immune cells but also the endothelial cells that line blood vessels in the tumor microenvironment. The study demonstrates that these vesicles can enhance angiogenesis, the process by which new blood vessels form from existing ones. This is crucial for tumors, which depend on a robust vascular supply to thrive and metastasize. The modulation of endothelial cell metabolism by tumor-derived EVs exemplifies the multifaceted nature of the tumor-immune interface.

Another striking finding from Zeng et al. is the connection between extracellular vesicles and the development of resistance to immunotherapy. Cancer immunotherapy, while having revolutionized the treatment landscape for many malignancies, is not universally effective. The presence of tumor-derived EVs has been shown to correlate with poorer outcomes in patients undergoing such therapies, suggesting that these vesicles may contribute to treatment failure. The study reveals that by downregulating immune checkpoint markers and influencing various signaling pathways involved in immune activation, EVs can create an environment resistant to the effects of therapeutic agents.

Zeng and colleagues also introduce new potential therapeutic strategies that could harness this knowledge. Developing specific inhibitors or modifiers of extracellular vesicle function could improve the efficacy of existing immunotherapies. Moreover, the study proposes the idea of engineering EVs to carry therapeutic agents or immune modulators to re-educate T cells and other immune components. The clinical implications of these potential interventions could be profound, paving the way for more successful outcomes in cancer treatment.

Another fascinating angle explored in the study pertains to the hands of the tumor microenvironment—how it not only serves as a battlefield for immune and cancerous cells but also actively reshapes the immune landscape over time. Zeng et al. discuss the temporal dynamics of EV release in relation to tumor progression and treatment responses. This insight could lead to the development of biomarkers that help predict tumor behavior and responsiveness to therapies.

In addition, the researchers underline the need for a deeper understanding of the molecular constituents of tumor-derived EVs. The proteins, lipids, and RNA molecules carried in these vesicles often reflect the state of their parent tumor cells, making them potential biomarkers for diagnosis and prognosis. Zeng et al.’s work encourages a comprehensive analysis of the vesicular cargo to derive better insights into the tumor’s behavior and the immune landscape.

One cannot overlook the implications of this research on the personalized medicine front. The individual variability in EV profiles could inform tailored therapeutic strategies that consider a patient’s unique tumor environment and immune makeup. This could herald a transformative approach in oncology, moving away from a one-size-fits-all regimen to more nuanced, patient-specific therapies that enhance treatment efficacy while reducing adverse effects.

While the study’s findings are exciting, they also unveil a plethora of questions that demand further investigation. The specific mechanisms through which EVs mediate their effects on immune cells vary widely and are still not completely understood. Future research must aim to delineate these pathways, distinguishing between pro- and anti-tumor functions of different populations of EVs under various conditions. This understanding will be critical for designing rational therapeutic interventions.

Understanding the role of EVs in tumor biology also sheds light on the broader implications of cancer treatment in the context of other chronic diseases. As research in immunometabolism burgeons, the parallels between cancer and other conditions such as autoimmune diseases, obesity, and metabolic syndrome could illustrate fundamental biological processes governed by extracellular vesicles. Zeng et al.’s work is a pioneering step in bridging these fields and fostering a cohesive dialogue between cancer researchers and specialists in other areas of medicine.

As this area of research grows, multidisciplinary collaboration will be essential. The interplay of cancer biology, immunology, biochemistry, and clinical medicine highlights the complexity of developing effective treatment strategies. The work of Zeng et al. serves as a call to action for the scientific community to unify efforts, combining expertise from diverse fields to tackle the challenges posed by tumor-derived extracellular vesicles.

In conclusion, the study by Zeng and colleagues culminates in a significant advancement in our understanding of how tumor-derived extracellular vesicles alter immune responses and contribute to therapeutic resistance. By offering insights into these underlying mechanisms, the authors not only pave the way for innovative approaches to combat cancer but also challenge researchers to frame the ongoing narrative of cancer treatment in light of the evolving dynamics of the immune system. The potential for harnessing this knowledge to develop targeted therapies illuminates a hopeful path forward in the fight against cancer.

Subject of Research: Tumor-derived extracellular vesicles and their role in immunometabolic reprogramming and immunotherapeutic resistance.

Article Title: Mechanisms of tumor-derived extracellular vesicle-mediated immunometabolic reprogramming and immunotherapeutic resistance.

Article References:

Zeng, H., Zhang, R., Zhu, X. et al. Mechanisms of tumor-derived extracellular vesicle-mediated immunometabolic reprogramming and immunotherapeutic resistance.
Mol Cancer (2026). https://doi.org/10.1186/s12943-025-02556-8

Image Credits: AI Generated

DOI: 10.1186/s12943-025-02556-8

Keywords: extracellular vesicles, tumor biology, immunometabolism, immunotherapy resistance, cancer treatment, immune cell reprogramming, therapeutic strategies.

CD4+ T cells are the hallmark cellular targets of HIV infection, orchestrating immune responses by signaling and mobilizing other immune components. Yet, these cells can harbor the virus in a latent form for extended periods, escaping immune surveillance and antiretroviral therapies. The latent reservoir has persisted as a formidable challenge precisely because the molecular underpinnings of latency induction remained poorly understood. The current research delineates the sophisticated viral strategy that manipulates host transcriptional and epigenetic pathways, thereby inducing a dormancy program within infected CD4+ cells.

At the core of the study is the identification of a comprehensive reprogramming of infected CD4+ T cells toward a quiescent state—a controlled cellular pause that allows viral DNA to integrate into the host genome as a provirus without immediate activation or destruction. This transcriptionally silent state effectively cloaks the virus from the immune system. The researchers employed high-resolution single-cell transcriptomics coupled with epigenetic profiling, revealing a striking alteration in the expression of genes central to cell cycle progression, metabolic activity, and immune activation. These transcriptional shifts sculpt a niche where proviral latency is not only established but firmly maintained.

One of the most compelling aspects of the study is its detailed characterization of the molecular actors involved in this reprogramming. HIV infection was observed to upregulate specific host factors that enforce cellular quiescence, including cyclin-dependent kinase inhibitors and members of the FOXO family of transcription factors, which govern cellular homeostasis and longevity. Concurrently, viral proteins were shown to interface with chromatin remodeling complexes, thereby consolidating a repressive chromatin environment at the integrated proviral loci. This dual modulation ensures that the latent virus remains dormantly embedded within the host cell genome, ready to reactivate under favorable conditions.

This research leveraged state-of-the-art chromatin immunoprecipitation sequencing (ChIP-seq) and assay for transposase-accessible chromatin sequencing (ATAC-seq) techniques to map the epigenetic landscape of latently infected CD4+ T cells. The data uncovered a marked enrichment of repressive histone modifications, such as H3K27 trimethylation, around the proviral DNA, indicative of tightly packed chromatin and transcriptional repression. These epigenetic constraints represent a formidable barrier to the accidental activation of viral gene expression, which would otherwise expose the infected cell to immune clearance.

Notably, the study also advances our understanding of how metabolic reprogramming supports this quiescent state. Latently infected cells exhibited a metabolic signature congruent with reduced glycolytic flux and heightened reliance on oxidative phosphorylation. Such an energy shift is congruent with the low metabolic demands of quiescence, supporting cell survival and longevity without triggering immune activation or viral transcription. These findings underscore the virus’s capacity not only to silence its own genome but also to reshape the metabolic circuitry of its host cell to favor persistence.

Furthermore, the researchers revealed that the reprogramming extends to the immunological identity of infected CD4+ T cells. Latently infected cells showed diminished expression of activation markers and cytokine genes, effectively mimicking a subset of naturally quiescent memory T cells. This phenotypic camouflage likely contributes to immune evasion, as these cells no longer display the hallmarks that would typically signal ongoing infection or cellular distress. Such stealth tactics complicate efforts to purge latent reservoirs via immune-mediated approaches.

The implications of these findings for therapeutic strategies are profound. Current antiretroviral treatments successfully suppress active viral replication but fail to eradicate latent reservoirs, necessitating lifelong therapy. By illuminating the molecular framework through which HIV enforces latency, the study lays the groundwork for novel interventions aimed at the selective reversal or disruption of quiescence programs. Targeting key host factors that sustain latency or modulating the epigenetic environment could unleash the dormant virus, rendering it visible to the immune system and amenable to clearance.

Importantly, this research suggests that latency reversal agents (LRAs) may need to be finely tailored to disrupt the multilayered quiescence circuitry. Broad-spectrum LRAs that indiscriminately activate viral transcription have exhibited limited clinical success, partly due to the heterogeneity of latent reservoirs and the complex host-virus interactions described in this study. Precision approaches that dismantle the specific cellular reprogramming events induced by HIV could enhance the efficacy of latency reversal and the ultimate clearance of infected cells.

Moreover, the elucidation of metabolic dependencies in quiescent infected cells offers a tantalizing new axis for therapy development. Metabolic inhibitors that selectively alter the oxidative phosphorylation pathway may sensitize latent reservoirs to activation or apoptosis. Integrating metabolic modulation into HIV cure strategies represents a promising frontier informed directly by the mechanistic insights from this study.

The study also opens new avenues for biomarker discovery. The distinct transcriptional and epigenetic signatures of latently infected CD4+ T cells described herein could serve as molecular markers for the identification and quantification of reservoir cells in vivo. Accurate detection of these cells remains a critical challenge in both research and clinical monitoring, and the markers identified provide a compelling starting point for developing diagnostic assays.

Equally critical is the recognition that HIV’s manipulation of CD4+ T cell quiescence intersects with broader immunological processes governing T cell longevity and memory. The findings enrich our fundamental understanding of T cell biology, demonstrating how viruses can co-opt normal immune regulatory networks to ensure their survival. This conceptual advance holds potential implications beyond HIV, including other persistent viral infections and immune-related diseases.

The multidisciplinary approach employed in this research, combining virology, immunology, genomics, epigenetics, and metabolism, exemplifies the modern paradigm necessary to disentangle complex host-pathogen interactions. The integration of cutting-edge technologies allowed the team to capture a holistic picture of latency, illustrating the power of systems biology in infectious disease research.

Looking forward, the authors emphasize the necessity of validating these findings in primary human cells ex vivo and in clinical samples from HIV-positive individuals on suppressive therapy. Such studies will ascertain the translational relevance of the cellular reprogramming events identified and inform the design of latency-targeted therapies that are both safe and effective.

In sum, the work of Plasek Hegde and colleagues represents a monumental advance in comprehending HIV latency. By revealing how the virus rewires CD4+ T cells to enter a quiescent, proviral latent state, they have unlocked vital knowledge poised to inform the next generation of therapeutic interventions aimed at achieving a functional or sterilizing cure for HIV.

Subject of Research: HIV infection and its effects on CD4+ T cell quiescence and proviral latency.

Article Title: HIV infection reprogrammes CD4+ T cells for quiescence and entry into proviral latency.

Article References:
Plasek Hegde, L.M., Gunawardane, L.S., Niazi, F. et al. HIV infection reprogrammes CD4+ T cells for quiescence and entry into proviral latency. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02128-y

Image Credits: AI Generated

Immunotherapy has revolutionized cancer treatment by leveraging the patient’s own immune system to attack malignant cells. Despite its promise, the success of immunotherapies in solid tumors like non-small cell lung cancer (NSCLC) remains limited. A significant hurdle is the infiltration of pro-tumoral macrophages—immune cells that instead of combating cancer, help suppress the antitumor immune response. These macrophages create an immunosuppressive microenvironment, aiding tumor growth and survival. Prior assumptions held that such macrophages adopted their pro-cancer roles only after arriving at the tumor. The new findings overturn this idea by tracing the origin of this immune subversion back to the bone marrow, where macrophage precursors undergo critical changes.

Employing cutting-edge single-cell genomics and lineage-tracing technologies, the researchers mapped the developmental trajectory of bone marrow myeloid progenitor cells, the precursors to macrophages. Their analyses uncovered that tumors broadcast signals that deliver a “first hit” to these progenitor cells in the bone marrow. This initial exposure biases the developing immune cells toward an immunosuppressive phenotype even before they infiltrate the tumor. Later, once in the tumor microenvironment, a “second hit” acts as a catalyst that locks these macrophages into their pro-tumoral functions. This two-step model represents a paradigm shift in our understanding of immune cell education by cancer.

Dr. Samarth Hegde, the study’s lead author, highlights that the temporal aspect of immune suppression had been misunderstood for decades. Observing that immune cells are preconditioned within the bone marrow demands a radical rethink of therapeutic strategies. Traditional approaches focus predominantly on the tumor microenvironment, attempting to re-educate or inhibit macrophages after they have already entrenched themselves among cancer cells. This study suggests that such attempts might be inherently limited. Targeting the progenitor cells prior to their arrival at the tumor could prevent them from becoming immunosuppressive in the first place, thus preserving the immune system’s capacity to mount effective anticancer responses.

One of the most promising molecular candidates identified in this reprogramming process is NRF2, a transcription factor fundamentally involved in cellular stress responses and redox homeostasis. The research team discovered that NRF2 activity is modulated in bone marrow progenitor cells exposed to tumor-derived inflammatory signals, rewiring these cells’ genetic programs. This NRF2-driven reprogramming becomes fully operational when the progenitors differentiate into tumor-infiltrating macrophages, promoting immune suppression and tumor progression in both human patients and mouse models. Crucially, inhibiting NRF2—either through genetic manipulation or experimental pharmacological agents—significantly reduced the formation of suppressive macrophages and revitalized antitumor immunity in preclinical experiments.

Miriam Merad, MD, PhD, senior corresponding author and Chair of Immunology and Immunotherapy at Mount Sinai, emphasizes the translational potential of these findings. By targeting NRF2 signaling in bone marrow progenitors, it might be possible to halt the supply line of immunosuppressive macrophages at its source, essentially cutting off the tumor’s capacity to subvert the immune system. “Current immunotherapies largely address the tumor itself but fail to consider the precursor immune cells’ prior ‘education,’” Dr. Merad notes. “Early intervention at the progenitor stage could dramatically improve the durability of treatment responses and possibly reduce relapse rates.”

Additionally, this newly revealed mechanism of immune cell manipulation by tumors offers a compelling opportunity for diagnostic innovation. Since the reprogrammed myeloid progenitors circulate in the bloodstream before differentiating, blood-based tests could detect these “pre-programmed” immune cells, facilitating earlier diagnosis and enabling timely therapeutic intervention. Such liquid biopsies would mark a significant advance in personalized medicine, allowing clinicians to monitor immune cell states during treatment and remission with unprecedented precision.

The implications of this research extend well beyond lung cancer. The investigators plan to explore whether similar genetic and epigenetic mechanisms govern immune cell progenitor reprogramming in other malignancies and chronic inflammatory diseases such as aging, obesity, and atherosclerosis. These conditions often share dysregulated immune responses, and understanding the underlying molecular controls, including NRF2 signaling, may reveal new treatment opportunities. Moreover, aberrant immune cell proliferation outside of the bone marrow—called extramedullary hematopoiesis—is observed in some cancers, and the team aims to investigate if comparable molecular programs are at play there as well.

A critical future direction involves elucidating how NRF2 and related pathways influence the metabolic reprogramming of immune cells. Tumors are known to manipulate cellular metabolism to evade immunity, and dissecting these interactions at the molecular level may clarify how suppressive macrophages gain their functional phenotype. This could lead to novel metabolic interventions that complement existing immunotherapies, creating multi-pronged strategies to outsmart cancer.

The publication titled “Myeloid Progenitor dysregulation fuels immunosuppressive macrophages in tumors” represents a landmark achievement in cancer immunology. By highlighting how tumors manipulate immune cells from their earliest developmental stages, it provides a blueprint for the next generation of cancer therapies focused on the immune system’s origins rather than its endpoints. This foundational work not only advances scientific understanding but also heralds a promising translational leap toward more effective and durable treatment regimens for patients battling lung cancer and potentially other challenging diseases.

This discovery underscores the critical role of interdisciplinary collaboration and advanced technologies in unraveling the complexity of cancer biology. The team’s integration of genomics, immunology, and translational medicine exemplifies the frontier of precision immunology research, making Mount Sinai a leader in tackling the most stubborn challenges in oncology.

Subject of Research: Cells
Article Title: Myeloid Progenitor dysregulation fuels immunosuppressive macrophages in tumors
News Publication Date: 10-Sep-2025
Web References: https://www.nature.com/articles/s41586-025-09493-y
References: DOI 10.1038/s41586-025-09493-y
Keywords: Cancer immunotherapy

Type 1 diabetes is a chronic autoimmune condition characterized by the immune system mistakenly targeting and destroying pancreatic beta cells, which produce the hormone insulin pivotal to regulating blood glucose levels. Affecting approximately 1.3 million individuals in the United States alone, the condition currently lacks a definitive cure. Existing treatments largely rely on external insulin administration or, in select cases, transplantation of pancreatic islet cells, procedures fraught with complications including the lifelong necessity for immunosuppressive drugs.

The Mayo Clinic team, led by immunologist Dr. Virginia Shapiro, drew inspiration from oncological research that demonstrated how cancer cells cloak themselves with sialic acid molecules—a form of glycosylation that effectively masks them from immune recognition. This “sugar coating” is facilitated by the enzyme ST8Sia6, which adds sialic acid residues to the tumor cell surface, thereby diminishing immune cell activation and enabling tumor survival despite immune surveillance.

In an elegant twist, the researchers hypothesized that the same mechanism could be reversed or repurposed by decorating healthy cells with sialic acid, thereby inducing immune tolerance rather than evasion. Initial proof of concept utilized artificially induced diabetes models, showing promising results. The current preclinical study advances this concept by deploying transgenic engineering techniques to overexpress ST8Sia6 intrinsically in beta cells within spontaneously diabetic nonobese diabetic (NOD) mice models—a close analogue to human type 1 diabetes pathogenesis.

The engineered beta cells exhibited remarkable resilience, with a 90% efficacy in blocking the onset of diabetes in these models. This protection is conferred by the enhanced expression of sialic acid, which dampens the autoreactive immune attack. Unlike systemic immunosuppression, which indiscriminately blunts the entire immune system’s functionality, this localized immune modulation maintains overall immunocompetence. Active B and T lymphocytes, crucial components of immune defense, remain unhampered and capable of mounting responses against unrelated pathogenic threats.

Crucially, the immune tolerance induced by ST8Sia6 appears highly specific to the beta cells, mitigating autoimmune rejection without generalized immune suppression. This specificity offers a paradigm shift in treating autoimmune diseases: rather than broadly weakening immunity, therapies can be tailored to protect vulnerable cells in a targeted fashion. Such an approach could avoid the common adverse effects associated with immunosuppressants, including opportunistic infections and malignancies.

The mechanistic underpinnings stem from altered glycosylation patterns on the beta cell surface. By overexpressing ST8Sia6, the beta cells increase sialic acid moieties, which engage inhibitory receptors on immune cells, such as Siglecs (sialic acid-binding immunoglobulin-type lectins). These receptors transduce signals that attenuate immune cell activation and proliferation, thereby fostering a microenvironment conducive to cell survival. This glycoengineering strategy exemplifies how nuanced manipulation of cell surface chemistry can recalibrate immune responses in autoimmunity.

From a translational perspective, these findings herald a potential breakthrough in beta cell transplantation for type 1 diabetes. Current islet transplantation therapies necessitate lifelong immunosuppressive regimens to prevent graft rejection, significantly limiting their applicability and exposing patients to adverse side effects. Incorporating ST8Sia6-overexpressing beta cells into transplantation protocols may circumvent the need for systemic immunosuppression, offering a safer and more durable therapeutic avenue.

While these studies remain preclinical, the implications are vast. Dr. Shapiro’s team emphasizes that this is an early yet critical step toward engineering immune-tolerant cellular therapies. Future research will focus on optimizing the stability and functionality of engineered beta cells in vivo, navigating regulatory pathways, and ultimately transitioning to human clinical trials. This work exemplifies the power of interdisciplinary research bridging oncology, glycoscience, and immunotherapy to address some of medicine’s most intractable challenges.

Furthermore, this discovery suggests broader applications beyond type 1 diabetes. The concept of modulating immune recognition via glycoengineering could be adapted to other autoimmune conditions where aberrant immune targeting of self-tissues underlies disease pathology. By tailoring the glycan “code” on vulnerable cells, it may be possible to selectively induce tolerance while preserving global immune competency.

The research was meticulously documented in the Journal of Clinical Investigation, reflecting robust experimental design and comprehensive analysis. Data revealed that despite local immunomodulation, systemic immunity remains vigilant, reinforcing the safety profile of this approach. The dual-degree candidate Justin Choe, M.D.-Ph.D., was the first author and contributed significantly to the experimental and conceptual advances underpinning these findings.

This innovative research, funded by grants from the National Institutes of Health, substantiates the growing recognition that immune evasion mechanisms in cancer can provide valuable insights for treating autoimmune diseases. The repurposing of these pathways underscores a transformative era in biomedical sciences where cross-disciplinary insights drive novel therapeutic strategies.

In summary, by harnessing the enzyme ST8Sia6 to enhance sialic acid expression on pancreatic beta cells, the Mayo Clinic team has charted a promising course toward developing immune-tolerant cell therapies that may one day revolutionize type 1 diabetes treatment, offering hope to millions worldwide.

Subject of Research: Engineering pancreatic beta cells through ST8Sia6 overexpression to prevent autoimmune destruction in type 1 diabetes

Article Title: ST8Sia6 overexpression protects pancreatic β cells from spontaneous autoimmune diabetes in nonobese diabetic mice

News Publication Date: 1-Aug-2025

Web References:

• Study in Journal of Clinical Investigation
• Mayo Clinic
• Type 1 Diabetes Information

References:

• Shapiro, V. M., et al. “ST8Sia6 overexpression protects pancreatic β cells from spontaneous autoimmune diabetes in nonobese diabetic mice.” Journal of Clinical Investigation, August 2025.
• Choe, J., et al. (First author)

Keywords: type 1 diabetes, autoimmune, ST8Sia6, sialic acid, pancreatic beta cells, immune tolerance, glycoengineering, islet transplantation, immune evasion, nonobese diabetic mice, Mayo Clinic, immunotherapy

At the heart of this discovery is the protein Argonaute 2 (AGO2), a key effector in the RNAi pathway that normally modulates gene expression post-transcriptionally in the cytoplasm. Intriguingly, the influenza virus manipulates AGO2 to relocate into the cell nucleus—a location where this protein rarely operates under normal physiological conditions. This nuclear relocalization enables the virus to strategically silence genes essential for the activation of type I interferons, molecules critical for initiating antiviral defense signals in neighboring uninfected cells.

Type I interferons act as alarm substances, orchestrating the immune system’s preparedness to viral invasion by enhancing the antiviral state of cells. By dampening the expression of interferon-related genes through AGO2’s aberrant activity within the nucleus, the influenza virus effectively muffles these alarm signals, blunting the host’s immune alert system and facilitating unchecked viral replication. This finding unveils a previously unanticipated nuclear function of AGO2 exploited by the virus, challenging traditional views of RNAi localization and immune modulation.

Key experiments demonstrated that AGO2 is ferried into the nucleus alongside the tumor suppressor protein p53, which is well-known for its role in DNA damage responses and transcriptional regulation. Once inside the nucleus, AGO2 associates directly with chromatin regions that regulate interferon gene expression, functioning as a repressive factor. This interaction effectively turns off critical immune genes, thereby sabotaging the cellular defense mechanisms at a genetic level.

The implications of this study extend beyond virology into the broader understanding of RNAi dynamics, as it reveals that RNAi effectors like AGO2 can be co-opted to influence nuclear gene transcription under pathological stress. The influenza A virus ingeniously manipulates this dual role of AGO2 to subvert host immunity, highlighting the sophistication of viral-host interactions evolved over millennia.

Prompted by these insights, the team investigated whether disrupting the virus’s ability to commandeer AGO2 would restore immune function and inhibit viral propagation. Encouragingly, the researchers employed arsenic trioxide (ATO), a drug already in clinical use for acute promyelocytic leukemia, hypothesizing that it could interfere with AGO2’s nuclear functions. Treatment with ATO in both cultured cells and infected mice resulted in a marked increase in type I interferon production and a concomitant decrease in viral load within the lungs, underscoring the therapeutic potential of targeting host pathways rather than viral components alone.

This approach signifies a paradigm shift in antiviral strategies, focusing on reinforcing endogenous cellular defenses instead of directly attacking the virus—a tactic that could circumvent common issues of antiviral resistance. By modulating RNAi machinery, specifically AGO2’s nuclear activity, it may be possible to develop broad-spectrum antivirals effective not only against influenza but potentially other RNA viruses with similar immune evasion strategies.

One of the senior authors, Aishe Sarshad, an associate professor of cellular and molecular biology at the University of Gothenburg’s Sahlgrenska Academy, emphasized the novelty of these findings: “It was astonishing to observe how influenza virus hijacks such a fundamental and finely tuned system as RNA interference—especially within the nucleus where AGO2’s regulatory roles have been largely uncharted until now.”

Beyond the molecular discoveries, the study expands the landscape of immunological research by demonstrating a novel viral mechanism that suppresses innate immune signaling pathways at the transcriptional level. This adds a critical piece to the puzzle of how influenza A evades immune detection and persists within the host environment, contributing to its global burden of seasonal epidemics and pandemics.

The collaborative work, much of which was conducted by postdoctoral researcher Hsiang-Chi Huang, delineates the detailed molecular interplay between AGO2, p53, and interferon-related genes, revealing a complex network exploited by viral infection. This intricate interplay not only suppresses antiviral responses but may also influence viral pathogenicity and disease severity.

Looking forward, the research team intends to explore whether similar nuclear hijacking of AGO2 or related RNAi components occurs in infections by other RNA viruses, which could open avenues for a universal antiviral therapy approach. The possibility of manipulating the host’s own RNAi mechanisms to augment immunity against diverse viral pathogens underscores the significance of this discovery.

In conclusion, this study pioneers a novel understanding of influenza A virus-host interactions, identifying nuclear AGO2 as a critical player in viral immune evasion and demonstrating the therapeutic promise of arsenic trioxide in restoring immune function. These findings could revolutionize antiviral treatment paradigms, shifting the focus toward modulation of host gene regulatory systems in the battle against viral diseases.

Subject of Research: Animals

Article Title: Nuclear AGO 2 Supports Influenza A Virus Replication through type-I interferon regulation

News Publication Date: 12-Apr-2025

Web References: http://dx.doi.org/10.1093/nar/gkaf268

Image Credits: Photo: Johan Wingborg (Aishe Sarshad and Davide Angeletti, Sahlgrenska Academy at the University of Gothenburg)

Keywords: Influenza A virus, AGO2, RNA interference, type I interferons, immune evasion, arsenic trioxide, antiviral therapy, nuclear gene regulation, p53, RNA viruses, host-pathogen interaction